Oruka Therapeutics, Inc. (ORKA)
$80.35-2.14%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3.0B
- Beta
- -0.39
- P/E (TTM)
- -32.46
- Short % float
- 29.38%
- Days to cover
- 6.3
- SI change
- +2.0%
- 1W
- -4.78%
- 1M
- -13.02%
- vs SPY 1W
- -5.20%
- vs SPY 1M
- -15.08%
Industry peers
FMP comparable companies · ranked by market cap
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.43-0.97%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 16$24.50+1.66%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$46.21+0.20%
- MLTXSELLMoonLake Immunotherapeutics$890MCRISISQ -0$10.58-1.29%
- ODTXSELLOdyssey Therapeutics, Inc.$870MQ 31$18.12-3.89%
- ALMSSELLAlumis Inc.$860MCRISISQ 1$6.97-1.40%
- ATTOSELLAttovia Therapeutics, Inc.$702MQ -47$16.31-9.99%
- ACRSSELLAclaris Therapeutics, Inc.$529MCRISISQ 9$3.79-6.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ORKA?
- LOPJLB’s latest quantitative signal on Oruka Therapeutics, Inc. (ORKA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ORKA in?
- Oruka Therapeutics, Inc. (ORKA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Oruka Therapeutics, Inc. (ORKA) do?
- Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleuki…